CLAIMS

1. Use of a therapeutic composition comprising allogeneic Th1 cells in the manufacture of a medicament for decreasing the immunosuppressive activity of Treg cells in a patient by modulating the activity of FoxP3, wherein decreasing and/or inhibiting the activity of the Treg cells: i) reduces the immune tolerance of disease antigens in the patient; ii) induces a therapeutic effect against a disease in the patient; or iii) reduces the immunosuppressive functions in the patient.

2. The use according to claim 1 wherein the Treg cells are CD4+CD25+FoxP3+.

3. The use according to claim 1 wherein the suppressive activity of the Treg cells is inhibited by decreasing the conversion of naïve T cells (CD4CD25-FoxP3-) to iTreg cells.

4. The use according to claim 1 wherein the suppressive activity of the Treg cells is by inhibition of nTreg cells.

5. The use according to claim 1 wherein the therapeutic composition comprises allogeneic emTh1 cells.

6. The use according to claim 1 wherein the therapeutic composition further comprises disease antigens or lysates associated with the disease antigens.

7. The use according to claim 1 wherein the therapeutic composition further comprises: i) IFNγ; ii) components that interact and reduce the activity of TGF-beta; or CD40L.

8. The use according to claim 1 wherein the disease is cancer or an infectious disease.

9. Use of activated Th1 cells and a source of disease antigens in the manufacture of a medicament for suppressing immune tolerance and promoting a therapeutic effect in a patient with a disease by modulating the activity of FoxP3, wherein the Th1 cells and the disease antigens are to be administered at the same location.

10. The use according to claim 9 wherein: the Th1 cells and the disease antigens are to be administered by intradermal injections and/or the activated Th1 cells are to be administered prior to the source of disease antigens.

11. The use according to claim 9 wherein the Th1 cells are allogeneic emTh-1 cells.

12. The use according to claim 9 wherein the source of disease antigens is CRCL.

13. The use according to claim 9 wherein the Th1 cells and the source of disease antigens are to be administered at least 3 times and at intervals of about 3-10 days until the patient exhibits a therapeutic effect.

14. Use of a source of disease antigens in the manufacture of a medicament for suppressing immune tolerance and promoting a therapeutic effect in a patient with a disease by modulating the activity of FoxP3, wherein the patient has received activated Th1 cells, and wherein the Th1 cells and the disease antigens are to be administered at the same location.

15. The use according to claim 6, wherein the therapeutic composition further comprises chaperone rich cell lysate of the disease antigens.